Tissue inhibitor of metalloproteinases 1 (TIMP1) has become a marker of prognosis and indicator for checking the clinical response in cancer treatment because TIMP1 is elevated in breast, colon, and prostate cancer patient plasma [42,43]. Here, TIMP1 is linked to cancer.